Exploring the Role of Overall Survival in Chemotherapy Protocol: A Literatur Review
Telaah Pustaka Penilaian Overall Survival Sebagai Parameter Klinis Tata Terapi Kanker
Keywords:
cancer malignancy, chemotherapy protocols, survivalAbstract
Overall survival (OS) assesses the patient's survival rate after undergoing therapy. The evaluation of OS becomes a reliable clinical endpoint for assessing the malignancy response to chemotherapy intervention. Here in, we review a number of publications on PCR data in various chemotherapy protocols for different types of cancer. The literature review involves nine scientific articles that meet the inclusion criteria provided by the PubMed database. Our findings present the performance of chemotherapy protocols with the highest OS values for each type of cancer, including: Non-Small Cell Lung Cancer Metastasis (Durvalumab plus Tremelimumab-31.2), Non-Metastatic Non-Small Cell Lung Cancer (Nivolumab-30.8), Small Cell Lung Cancer (Carboplatin and Etoposide-13.2), Breast Cancer (Ribociclib plus Fulvestrant-67.6), Metastatic Breast Cancer (Olaparib-18.9), Metastatic Colorectal Cancer (Trifluridine/tipiracil-13.1), Liver Cancer (SBRT 44.1). This article reviews a number of publications on PCR data in various chemotherapy protocols for different types of cancer.
References
C. He, Y. Zhang, Z. Cai, X. Lin, dan S. Li, “Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing risk nomogram analysis,” J. Cancer, vol. 9, no. 17, hal. 3156–3167, 2018, doi: 10.7150/jca.25494.
E. L. Korn, B. Freidlin, dan J. S. Abrams, “Overall survival as the outcome for randomized clinical trials with effective subsequent therapies.,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 29, no. 17, hal. 2439–2442, Jun 2011, doi: 10.1200/JCO.2011.34.6056.
E. S. Sinaga, R. A. Ahmad, S. Shivalli, dan S. H. Hutajulu, “Age at diagnosis predicted survival outcome of female patients with breast cancer at a tertiary hospital in Yogyakarta, Indonesia,” Pan Afr. Med. J., vol. 31, hal. 1–9, 2018, doi: 10.11604/pamj.2018.31.163.17284.
M. Ayuza, W. A. Harahap, R. Rustam, dan R. D. Nindrea, “Faktor yang Berpengaruh Terhadap Disease Free Survival dan Overall Survival pada Pasien Kanker Payudara Usia Muda di Kota Padang Tahun 2008 - 2018,” J. Kesehat. Andalas, vol. 9, no. 1S, hal. 65–73, 2020, doi: 10.25077/jka.v9i1s.1157.
D. N. Hikmah, A. Syarifuddin, S. B. Santoso, R. Wijayatri, dan I. W. Hidayat, “The Role of Genetic Mutation on Schizophrenia: A Basic Review Prior to Pharmacogenomics,” vol. 2022, hal. 835–847, 2024, doi: 10.2991/978-2-38476-118-0_96.
S. S. Zahrah, R. Wijayatri, I. W. Hidayat, A. Syarifuddin, dan S. B. Santoso, From the Genetic Mutation to the Specific Pathologies, vol. 2. Atlantis Press SARL, 2024. doi: 10.2991/978-2-38476-118-0_49.
S. B. Santoso, P. Pribadi, dan L. M. Irham, “Isoniazid-induced liver injury risk level in different variants of N-acetyltransferase 2 (NAT2) polymorphisms: A literature review,” Pharmacia, vol. 70, no. 4, hal. 973–981, 2023, doi: 10.3897/pharmacia.70.e109869.
Rifqi, M. Lutfi, dan H. Pradjatmo, “Hubungan Nilai Rasio Neutrofil-Limfosit Pra Pembedahan dengan Prognosis Kanker Ovarium Jenis Epitelial di RSUP Dr . Sardjito,” vol. 896, no. Icm, 2023, doi: 10.22146/jkr.65530.
M. R. Widyaningrum, W. Soewoto, I. Bagus, dan B. Surya, “Overall Survival Rate and Recurrence Free Survival Rate in Breast Sarcoma Patients : Single Center 5-Years Retrospective Study,” vol. 4, no. 3, hal. 30–39, 2021.
Z. Zubaidah, R. J. Sitorus, R. Flora, dan K. Tantrakarnapa, “the Three-Year Survival Rate of Cervical Cancer Patients At Referral Hospital in Southern Sumatra, Indonesia,” J. Berk. Epidemiol., vol. 10, no. 2, hal. 121–129, 2022, doi: 10.20473/jbe.v10i22022.121-129.
H. A. Sjakti, I. A. Putri, dan E. Windiastuti, “Survival rates of pediatric osteosarcoma in Indonesia: a single center study,” Paediatr. Indones. Indones., vol. 62, no. 1, hal. 27–31, 2022, doi: 10.14238/pi62.1.2022.27-31.
Y. Cheng et al., “NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer,” Lung Cancer, vol. 178, no. January, hal. 87–95, 2023, doi: 10.1016/j.lungcan.2023.01.013.
H. R. Kim et al., “First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial.,” Cancer Med., vol. 12, no. 16, hal. 17061–17067, Agu 2023, doi: 10.1002/cam4.6348.
T. Makharadze et al., “Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial,” J. Thorac. Oncol., vol. 18, no. 6, hal. 755–768, 2023, doi: 10.1016/j.jtho.2023.03.008.
T. Shimokawa et al., “Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial,” Lung Cancer, vol. 181, no. January, hal. 107195, 2023, doi: 10.1016/j.lungcan.2023.107195.
P. Neven et al., “Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant,” Breast Cancer Res., vol. 25, no. 1, hal. 103, 2023, doi: 10.1186/s13058-023-01701-9.
M. E. Robson et al., “OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer,” Eur. J. Cancer, vol. 184, hal. 39–47, 2023, doi: 10.1016/j.ejca.2023.01.031.
S. Napolitano et al., “ Panitumumab plus trifluridine/tipiracil as anti? EGFR rechallenge therapy in patients with refractory RAS wild?type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial ,” Int. J. Cancer, no. March, hal. 1520–1528, 2023, doi: 10.1002/ijc.34632.
A. Méndez Romero et al., “Transarterial Chemoembolization With Drug-Eluting Beads Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Outcomes From a Multicenter, Randomized, Phase 2 Trial (the TRENDY Trial),” Int. J. Radiat. Oncol. Biol. Phys., vol. 117, no. 1, hal. 45–52, 2023, doi: 10.1016/j.ijrobp.2023.03.064.
N. Andayani dan L. Julisafrida, “Peranan Immunoterapi Pada Kanker Paru,” J. Kedokt. Syiah Kuala, vol. 20, no. 2, hal. 70–77, 2020, doi: 10.24815/jks.v20i2.18499.
H. Borghaei et al., “Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer,” N. Engl. J. Med., vol. 373, no. 17, hal. 1627–1639, 2015, doi: 10.1056/nejmoa1507643.
S. N. Gettinger et al., “Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer,” J. Clin. Oncol., vol. 33, no. 18, hal. 2004–2012, 2015, doi: 10.1200/JCO.2014.58.3708.
K. A. . N. Marrone Jarushka; Brahmer, Julie R., “Immunotherapy for Lung Cancer: No Longer an Abstract Concept,” Semin Respir Crit Care Med, vol. 37, no. 05, hal. 771–782, 2016, doi: 10.1055/s-0036-1592298.
D. Tripathy, A. Bardia, dan W. R. Sellers, “Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors,” Clin. Cancer Res., vol. 23, no. 13, hal. 3251–3262, 2017, doi: 10.1158/1078-0432.CCR-16-3157.
M. R. Nathan dan P. Schmid, “A Review of Fulvestrant in Breast Cancer,” Oncol. Ther., vol. 5, no. 1, hal. 17–29, 2017, doi: 10.1007/s40487-017-0046-2.
D. J. Slamon et al., “Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer,” N. Engl. J. Med., vol. 382, no. 6, hal. 514–524, Des 2019, doi: 10.1056/NEJMoa1911149.
R. Dubia?ski, “Effect of ribociclib plus fulvestrant on overall survival in the treatment of advanced breast cancer — updated MONALEESA-3 results,” Oncol. Clin. Pract., vol. 18, no. 3, hal. 189–194, 2022, doi: 10.5603/OCP.2021.0034.
E. Van Cutsem et al., “The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer,” Eur. J. Cancer, vol. 90, hal. 63–72, 2018, doi: 10.1016/j.ejca.2017.10.009.
M. Peeters, A. Cervantes, S. Moreno Vera, dan J. Taieb, “Trifluridine/tipiracil: An emerging strategy for the management of gastrointestinal cancers,” Futur. Oncol., vol.14, no. 16, hal. 1629–1645, 2018, doi: 10.2217/fon-2018-0147.
E. Van Cutsem et al., “Tri fl uridine / tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy : the randomized TASCO1,” Ann. Oncol., vol. 31, no. 9, hal. 1160–1168, 2020, doi: 10.1016/j.annonc.2020.05.024.
H. S. Choi et al., “Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease.,” Asia. Pac. J. Clin. Oncol., vol. 17, no. 3, hal. 209–215, Jun 2021, doi: 10.1111/ajco.13361.
T. Arizumi et al., “The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization,” Liver Cancer, vol. 6, no. 3, hal. 227–235, 2017, doi: 10.1159/000475777.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
